ATH-1105 – A next-generation, novel, orally administered, small molecule drug candidate in development for the potential treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative ...
A fundraiser has been launched for Will Vess, a 57-year-old retired United States Air Force veteran who was recently ...
Her husband, Scott Sessa, said that her death, in a hospital, was caused by complications of amyotrophic lateral sclerosis ...
The event was initially reported as motor neuropathy, which was later defined as amyotrophic lateral sclerosis (ALS), a ...
Our pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and ...
The event was initially reported as motor neuropathy, which was later defined as amyotrophic lateral sclerosis (ALS), a ...
Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...
The condition is a rapidly progressive neurodegenerative disorder leading to wasting, paralysis, and eventual death from ...
The FDA initially halted the trials on 16 October after a patient in the Phase II trial (NCT05519839) of the CIC vaccine ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
The event, originally described as motor neuropathy, was later reclassified as amyotrophic lateral sclerosis. The FDA requested additional information, which Novavax provided, confirming that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback